Loading clinical trials...
Loading clinical trials...
A Pharmacokinetic/Pharmacodynamic Evaluation of ABF656 in Subjects With Chronic Hepatitis B, e Ag+, Infection.
Conditions
Interventions
albinterferon alfa-2b
albinterferon alfa-2b
+3 more
Locations
12
China
Novartis Investigator Site
Beijing, China
Novartis Investigator Site
Shatin, Hong Kong
Novartis Investigator Site
Taipo, Hong Kong
Novartis Investigator Site
Bialystok, Poland
Novartis Investigator Site
Lodz, Poland
Novartis Investigator Site
Warsaw, Poland
Start Date
July 1, 2009
Primary Completion Date
November 1, 2010
Last Updated
January 6, 2011
NCT06671093
NCT06885710
NCT06263959
NCT06295328
NCT02883647
NCT04139850
Lead Sponsor
Novartis Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions